<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="117665">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01571232</url>
  </required_header>
  <id_info>
    <org_study_id>IIT-406</org_study_id>
    <nct_id>NCT01571232</nct_id>
  </id_info>
  <brief_title>Ozurdex for Treatment of Recalcitrant Diabetic Macular Edema</brief_title>
  <official_title>Ozurdex for Treatment of Recalcitrant Diabetic Macular Edema.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Retina Macula Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Retina Macula Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test the efficacy of an 0.7 mg intravitreal dexamethasone
      implant (Ozurdex®) on macular leakage and visual acuity for patients with recalcitrant
      diabetic macular edema.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label, Phase II comparative study of an intravitreal dexamethasone implant
      versus intravitreal bevacizumab (Avastin) in 20 patients with recalcitrant diabetic macular
      edema and prior treatment with ≥ 2 intravitreal anti-VEGF injections.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2012</start_date>
  <completion_date type="Anticipated">June 2013</completion_date>
  <primary_completion_date type="Anticipated">June 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single Blind (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The change in visual acuity (number of ETDRS letters).</measure>
    <time_frame>6 months</time_frame>
    <description>The measure the change in ETDRS letters for each treatment group from baseline to 6 months.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The change in central foveal thickness (microns on high resolution OCT).</measure>
    <time_frame>6 months</time_frame>
    <description>The measure the change in central foveal thickness for each treatment group from baseline to 6 months.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The change in macular leakage on fluorescein angiography from baseline</measure>
    <time_frame>6 months</time_frame>
    <description>To qualitatively assess the change in macular leakage on fluorescein angiography from baseline to 6 months for each treatment arm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change in mean macular sensitivity on microperimetry from baseline</measure>
    <time_frame>6 months</time_frame>
    <description>To assess the change in macular sensitivity on microperimetry from baseline to 6 months for each treatment arm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change in mean central amplitude on multi-focal ERG from baseline.</measure>
    <time_frame>6 months</time_frame>
    <description>To assess the change in mean central amplitude on multi-focal ERG from baseline to 6 months for each treatment arm.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Diabetic Macular Edema.</condition>
  <condition>Non-proliferative Diabetic Retinopathy</condition>
  <condition>Proliferative Diabetic Retinopathy</condition>
  <arm_group>
    <arm_group_label>Ozurdex</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in this group receive Ozurdex at initial visit and at month 4</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Avastin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in this group receive Avastin Q1 month for 5 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dexamethasone intravitreal implant</intervention_name>
    <description>Ozurdex, 0.7 mg intravitreal dexamethasone implant, given at initial visit and at month 4 (visit 5)</description>
    <arm_group_label>Ozurdex</arm_group_label>
    <other_name>Ozurdex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>intravitreal bevacizumab</intervention_name>
    <description>Avastin, 1.25 mg intravitreal bevacizumab, given at initial visit and Q1month for a total of 5 treatments.</description>
    <arm_group_label>Avastin</arm_group_label>
    <other_name>Avastin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Presence of NPDR or PDR as confirmed by fluorescein angiography

          -  Prior treatment with &gt;= 2 intravitreal anti-VEGF injections but no treatment in last
             4 weeks

          -  &lt; 0.1 LogOCT decrease in macular edema on high resolution OCT between initial visit
             and following treatment with &gt;= 2 intravitreal anti-VEGF injections

          -  Age 18 years or older

          -  ETDRS Visual acuity between 3 and 78 letters (approximate Snellen equivalent of 20/25
             to 20/800)

          -  Ability to provide written informed consent

          -  Capable of complying with study protocol.

        Exclusion Criteria:

          -  Intraocular injection of steroid medication within prior 3 months

          -  Evidence of significant geographic atrophy on fluorescein angiography in the opinion
             of the treating physician

          -  Concurrent ocular disease (wet AMD, significant ERM, etc) that would limit visual
             acuity in the opinion of the treating physician

          -  Prior vitrectomy surgery

          -  Use of systemic steroids (eg, oral, intravenous, intramuscular, epidural, rectal, or
             extensive dermal) within 1 month prior to day 1.

          -  Known history of IOP elevation in response to steroid treatment in either eye that
             resulted in any of the following: a) = 10 mm Hg increase in IOP in response to
             steroid injection, or b) IOP = 25 mm Hg and required 2 or more anti-glaucoma
             medications to keep IOP below 21 mm Hg.

          -  Patients who are pregnant.

          -  Unwilling or unable to follow or comply with all study related procedures
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ron P Gallemore, M.D, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Retina Macula Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Behnam Sharareh, B.S</last_name>
    <role>Study Director</role>
    <affiliation>Retina Macula Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gina Kim, B.S</last_name>
    <phone>310-944-9393</phone>
    <email>gina.kim@retinamaculainstitute.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Retina Macula Institute</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90503</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gina Kim, B.S</last_name>
      <phone>310-944-9393</phone>
      <email>gina.kim@retinamaculainstitute.com</email>
    </contact>
    <investigator>
      <last_name>Ron P Gallemore, M.D, Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mehran Taban, M.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ray Oyakawa, M.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Behnam Sharareh, B.S</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <lastchanged_date>January 13, 2013</lastchanged_date>
  <firstreceived_date>April 2, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Retina Macula Institute</investigator_affiliation>
    <investigator_full_name>Ron P. Gallemore</investigator_full_name>
    <investigator_title>Physician and CEO of Retina Macula Institute</investigator_title>
  </responsible_party>
  <keyword>Macular Edema</keyword>
  <keyword>DME</keyword>
  <keyword>PDR</keyword>
  <keyword>NPDR</keyword>
  <keyword>Ozurdex</keyword>
  <keyword>Dexamethasone</keyword>
  <keyword>Avastin</keyword>
  <keyword>Bevacizumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Macular Edema</mesh_term>
    <mesh_term>Edema</mesh_term>
    <mesh_term>Retinal Diseases</mesh_term>
    <mesh_term>Diabetic Retinopathy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone 21-phosphate</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
